Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

US President Donald Trump announced plans to impose tariffs on imported computer chips pharmaceuticals and steel aiming to drive more manufacturing within the United States ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities. Japanese firms confront shifting priorities in specialized therapies, ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK ... Regulatory applications are under review in the EU, Japan and several other countries based on the DESTINY-Breast06 results. AZN closed Monday's ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

The comments mark the latest in a number of trade-related threats unleashed by Trump in recent days. Trump said he plans to ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

By focusing on chips and pharmaceuticals, Trump could squeeze US allies in Asia, including Taiwan, South Korea and Japan.